Mirdametinib for NF1-related high-grade brain tumors
Treatments studied
Part of Brain & nervous system, Cancer, Genetic & congenital clinical trials.
This trial tests a drug called mirdametinib, alone or combined with radiation, to treat high-grade gliomas (aggressive brain or spinal cord tumors) in people with neurofibromatosis type 1 (NF1) or those whose tumors have NF1 gene changes. The drug targets a specific pathway that may help slow or stop these tumors from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a high-grade glioma (aggressive brain or spinal cord tumor) that has been confirmed by pathology testing and genetic analysis
- You meet age and health requirements: at least 12–18 years old (depending on tumor type) and able to perform daily activities at a reasonable level
- Your blood counts, kidney function, and liver function are adequate; your blood pressure is controlled
- You have waited the required time since your last cancer treatment (typically 2–24 weeks, depending on the type of treatment)
- You have tumor tissue available for testing, and you have recovered from side effects of prior treatments to mild levels or less
- You are not pregnant or breastfeeding, have no uncontrolled heart or eye conditions, and can use effective birth control during and 6 weeks after the trial
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two targeted drugs (selumetinib and milademetan) for people with neurofibromatosis type 1 (NF1) who have either a malignant peripheral nerve sheath tumor (MPNST) or an atypical neurofibromatous neoplasm with uncertain biologic potential (ANNUBP). The goal is to see if blocking certain proteins can shrink or control these tumors.
This Phase 2 trial tests several targeted medicines (given together or by specific assignment) for meningiomas inside the brain that are progressing or not fully removed after surgery. It may help slow the tumor’s growth and improve symptoms by blocking tumor growth pathways.
This trial tests a combination of two oral medications for people who have just been diagnosed with a high-grade brain tumor. The goal is to see if the treatment is safe and feasible when given alongside standard radiation therapy.
This trial tests an experimental oral drug called mirdametinib for people with advanced melanoma that has a specific gene change (NF1 mutation). To join, you must have already had immunotherapy, but not a MEK/ERK/RAF targeted drug before.
This trial tests a drug called mirdametinib for people with specific types of brain tumors or neurohistiocytosis (a rare condition affecting the nervous system). The drug targets mutations that cause these conditions to grow.
This study tests an oral drug called mirdametinib to see if it can shrink skin bumps caused by NF1. If you have at least 24 of these bumps on your skin and are in decent health, you may be able to join.
Hear when a new Neurofibromatosis 1 (NF1) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.